These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 38675402)

  • 41. Lutein Supplementation for Eye Diseases.
    Li LH; Lee JC; Leung HH; Lam WC; Fu Z; Lo ACY
    Nutrients; 2020 Jun; 12(6):. PubMed ID: 32526861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ocular and systemic melatonin and the influence of light exposure.
    Ostrin LA
    Clin Exp Optom; 2019 Mar; 102(2):99-108. PubMed ID: 30074278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Melatonin and the control of intraocular pressure.
    Alkozi HA; Navarro G; Franco R; Pintor J
    Prog Retin Eye Res; 2020 Mar; 75():100798. PubMed ID: 31560946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Melatonin: an underappreciated player in retinal physiology and pathophysiology.
    Tosini G; Baba K; Hwang CK; Iuvone PM
    Exp Eye Res; 2012 Oct; 103():82-9. PubMed ID: 22960156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of Oxidative Stress in Ocular Diseases: A Balancing Act.
    Shu DY; Chaudhary S; Cho KS; Lennikov A; Miller WP; Thorn DC; Yang M; McKay TB
    Metabolites; 2023 Jan; 13(2):. PubMed ID: 36837806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing.
    Tan AY; LeVatte TL; Archibald ML; Tremblay F; Kelly ME; Chauhan BC
    J Glaucoma; 2002 Apr; 11(2):134-42. PubMed ID: 11912361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NOD-like Receptors in the Eye: Uncovering Its Role in Diabetic Retinopathy.
    Lim RR; Wieser ME; Ganga RR; Barathi VA; Lakshminarayanan R; Mohan RR; Hainsworth DP; Chaurasia SS
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019187
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments.
    Karakuş MM; Çalışkan UK
    Curr Mol Pharmacol; 2021; 14(5):689-713. PubMed ID: 33349225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization.
    Huang L; Liang W; Zhou K; Wassel RA; Ridge ZD; Ma JX; Wang B
    Biology (Basel); 2021 Dec; 10(12):. PubMed ID: 34943243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topical noninvasive retinal drug delivery of a tyrosine kinase inhibitor: 3% cediranib maleate cyclodextrin nanoparticle eye drops in the rabbit eye.
    Lorenzo-Soler L; Praphanwittaya P; Olafsdottir OB; Kristinsdottir IM; Asgrimsdottir GM; Loftsson T; Stefansson E
    Acta Ophthalmol; 2022 Nov; 100(7):788-796. PubMed ID: 35080812
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
    Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C
    Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of lipid peroxidation and electron microscopic survey of maturation stages during human cataractogenesis: pharmacokinetic assay of Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention.
    Babizhayev MA
    Drugs R D; 2005; 6(6):345-69. PubMed ID: 16274259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inflammation in Glaucoma: From the back to the front of the eye, and beyond.
    Baudouin C; Kolko M; Melik-Parsadaniantz S; Messmer EM
    Prog Retin Eye Res; 2021 Jul; 83():100916. PubMed ID: 33075485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of addition of nepafenac 0.1% to steroid eye drops in prevention of post-phaco macular edema in high-risk eyes.
    El Gharbawy SA; Darwish EA; Abu Eleinen KG; Osman MH
    Eur J Ophthalmol; 2019 Jul; 29(4):453-457. PubMed ID: 30203671
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The novel dopamine D-1 antagonist and D-2 agonist, SDZ GLC-756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma.
    Prünte C; Flammer J
    Ophthalmology; 1995 Sep; 102(9):1291-7. PubMed ID: 9097765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.
    Vaneev A; Tikhomirova V; Chesnokova N; Popova E; Beznos O; Kost O; Klyachko N
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830247
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alleviation of dry eye syndrome with one dose of antioxidant, anti-inflammatory, and mucoadhesive lysine-carbonized nanogels.
    Lin PH; Jian HJ; Li YJ; Huang YF; Anand A; Huang CC; Lin HJ; Lai JY
    Acta Biomater; 2022 Mar; 141():140-150. PubMed ID: 35081433
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adreno-melatonin receptor complexes control ion homeostasis and intraocular pressure - their disruption contributes to hypertensive glaucoma.
    Alkozi HA; Navarro G; Aguinaga D; Reyes-Resina I; Sanchez-Naves J; Pérez de Lara MJ; Franco R; Pintor J
    Br J Pharmacol; 2020 May; 177(9):2090-2105. PubMed ID: 31901203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circadian rhythms in the eye: the physiological significance of melatonin receptors in ocular tissues.
    Wiechmann AF; Summers JA
    Prog Retin Eye Res; 2008 Mar; 27(2):137-60. PubMed ID: 18316227
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.